Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
573 stopped studies mapped to Multiple Myeloma and descendants · 91% state a reason
Over the 573 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT00516191 | A Phase I/II Study of Liposomal Doxorubicin (Doxil)/Melphalan/Bortezomib (Velcade) in…(DMV) | Phase 1 / Phase 2 | withdrawn | Aug 15, 2007 | University of California, San Francisco | low accrual | Enrollment / accrual |
| NCT00891033 | Panobinostat/Velcade in Multiple Myeloma | Phase 1 | terminated | Apr 30, 2009 | University of Arkansas | This study was terminated because the drug company stopped making the study drug | Sponsor / business decision |
| NCT01449539 | Study of Hyperbaric Oxygen Therapy in Addition to Standard Growth Factor Support for… | N/A | terminated | Oct 10, 2011 | University of Arkansas | Study was terminated early because the site that administered the hyperbaric oxygen treatment… | Other (stated, no rule matched) |
| NCT01302366 | A Trial of TBL12 Sea Cucumber Extract in Patients With Untreated Asymptomatic Myeloma | Phase 2 | terminated | Feb 24, 2011 | NYU Langone Health | due to lack of funding | Funding |
| NCT01537861 | Filgrastim in Treating Patients With Bortezomib-, Carfilzomib-, or IMID-Refractory… | Early Phase 1 | terminated | Feb 23, 2012 | Washington University School of Medicine | Unexpected toxicity (2 early deaths) | Safety / toxicity |
| NCT00719901 | Obatoclax and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma | Phase 1 / Phase 2 | terminated | Jul 22, 2008 | National Cancer Institute (NCI) | This trial was terminated due to slow accrual and the drug supply of Obatoclax during the phase I;… | Drug supply |
| NCT01078441 | Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in… | Phase 2 | terminated | Mar 2, 2010 | National Cancer Institute (NCI) | The study was closed early due to weak accrual on June 26, 2012. | Enrollment / accrual |
| NCT01653418 | Phase II Study of V-BEAM Conditioning Regimen Prior to Second Autologous Stem Cell…(V-BEAM) | Phase 2 | terminated | Jul 31, 2012 | Washington University School of Medicine | Due to the high rate of morbidity and mortality | Other (stated, no rule matched) |
| NCT00594308 | In-Vivo Activated T-Cell Depletion to Prevent GVHD | N/A | terminated | Jan 15, 2008 | Indiana University | Treatment ineffective | Other (stated, no rule matched) |
| NCT00675428 | Study of Natalizumab in Relapsed/Refractory Multiple Myeloma | Phase 1 / Phase 2 | terminated | May 9, 2008 | Biogen | Sponsor decision due to low enrollment and not safety concerns. | Safety / toxicity |
| NCT00240162 | PTK/ZK as Post Transplant Maintenance Therapy in Patients With Multiple Myeloma | Phase 2 | terminated | Oct 17, 2005 | Washington University School of Medicine | investigator letter from drug manufacturer stating animal studies showed increased risk of cancer… | Safety / toxicity |
| NCT02115035 | A Single Agent Study to Evaluate the Overall Response Rate, Safety and Tolerability of… | Phase 1 / Phase 2 | withdrawn | Apr 15, 2014 | University of Arkansas | Funding issues | Funding |
| NCT01301963 | Filgrastim With or Without Plerixafor in Treating Patients With Multiple Myeloma… | Phase 3 | terminated | Feb 23, 2011 | Case Comprehensive Cancer Center | Slow Accrual | Enrollment / accrual |
| NCT02114502 | Carfilzomib/SAHA Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous… | Phase 2 | withdrawn | Apr 15, 2014 | M.D. Anderson Cancer Center | not stated | Not stated |
| NCT02079519 | A Study of Avastin (Bevacizumab) in Patients With Multiple Myeloma | Phase 2 | terminated | Mar 5, 2014 | Hoffmann-La Roche | The study was discontinued prematurely by the sponsor due to a lack of recruitment. | Enrollment / accrual |
| NCT00872300 | PHA-739358 for the Treatment of Multiple Myeloma | Phase 2 | terminated | Mar 31, 2009 | Nerviano Medical Sciences | Low recruitment rate | Enrollment / accrual |
| NCT01309412 | A Phase 1 Study of CNTO 328 (Siltuximab) in Relapsed or Refractory Multiple Myeloma | Phase 1 | terminated | Mar 7, 2011 | Janssen Pharmaceutical K.K. | Protocol was stopped due to the safety issue in Global | Safety / toxicity |
| NCT00293111 | Safety and Efficacy of SDX-101 (R-Etodolac) in Patients With Relapsed or Refractory… | Phase 2 | terminated | Feb 17, 2006 | Cephalon | not stated | Not stated |
| NCT00215943 | Phase III Randomized Trial of Thalidomide/Dexamethasone Versus… | Phase 3 | terminated | Sep 22, 2005 | H. Lee Moffitt Cancer Center and Research Institute | Poor accrual, changes in management of newly diagnosed myeloma patients, new drugs/more effective… | Enrollment / accrual |
| NCT00441168 | Velcade (Bortezomib), Adriamycin Dexamethasone (PAD) or Vincristine Adriamycin… | Phase 2 | terminated | Feb 28, 2007 | Janssen-Cilag International NV | TRIAL STOPPED due to a change in standard of care and the required patient numbers could no longer… | Other (stated, no rule matched) |
| NCT00943293 | Minor Histocompatibility Vaccination After Allogeneic Stem Cell Transplantation for… | Phase 1 | terminated | Jul 22, 2009 | University of Chicago | Poor accrual; did not enter phase 2 | Enrollment / accrual |
| NCT00396383 | Treatment With AMD3100 (Plerixafor) in MM Patients to Mobilize PBCs For Collection and… | Phase 2 | terminated | Nov 6, 2006 | Genzyme, a Sanofi Company | Insufficient cell mobilization for tandem transplants | Other (stated, no rule matched) |
| NCT00499239 | A Trial of GS-9219 in Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma (NHL) or… | Phase 1 / Phase 2 | terminated | Jul 11, 2007 | Gilead Sciences | Unacceptable safety profile | Safety / toxicity |
| NCT00590603 | Trisenox, Ascorbic Acid and Bortezomib in Patients With Relapsed/Refractory Multiple…(AAV) | Phase 1 | terminated | Jan 10, 2008 | Duke University | Poor accrual - terminated during Phase I; Phase II never started. | Enrollment / accrual |
| NCT00412919 | Study of Azacitidine to Treat Relapsed or Refractory Multiple Myeloma | Phase 2 | terminated | Dec 19, 2006 | Bayside Health | Lack of efficacy | Efficacy / futility |
| NCT00899353 | Prevention of Disease Progression in Early Stage Indolent B Cell Malignancies. (SMM) | Phase 2 | terminated | May 12, 2009 | Marshall University | Original Principal Investigator left the institution. | Investigator |
| NCT00361088 | A Combination of Zarnestra With Velcade for Patients With Relapsed Multiple Myeloma | Phase 1 / Phase 2 | terminated | Aug 7, 2006 | H. Lee Moffitt Cancer Center and Research Institute | Initial Principal Investigator left Moffitt | Investigator |
| NCT01500161 | Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing… | Phase 2 | terminated | Dec 28, 2011 | Texas Oncology Cancer Center | Insufficient accruals | Enrollment / accrual |
| NCT00718640 | An Efficacy and Safety Study of Bortezomib in Participants Previously Treated for… | Phase 2 | terminated | Jul 21, 2008 | Janssen-Ortho Inc., Canada | Study stopped due to lagging enrolment. | Enrollment / accrual |
| NCT00243035 | Tipifarnib and Bortezomib in Treating Patients With Relapsed Multiple Myeloma | Phase 1 / Phase 2 | terminated | Oct 21, 2005 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00965861 | SCRI Tissue Testing Registry | — | terminated | Aug 26, 2009 | SCRI Development Innovations, LLC | Replaced by a study with a similar design. | Other (stated, no rule matched) |
| NCT00514722 | Pilot Study of Umbilical Cord Blood Transplantation in Adult Patient With Advanced… | N/A | terminated | Aug 10, 2007 | University of California, San Francisco | low accrual | Enrollment / accrual |
| NCT00241371 | A Phase II Study of Clofarabine in Patients With Relapsed or Refractory Multiple Myeloma | Phase 2 | terminated | Oct 18, 2005 | Washington University School of Medicine | No response seen in patients | Other (stated, no rule matched) |
| NCT00513318 | Pilot Study of Reduced-Intensity Umbilical Cord Blood Transplantation in Adult Patients… | — | terminated | Aug 8, 2007 | University of California, San Francisco | Insufficient enrollment to justify keeping open. | Enrollment / accrual |
| NCT00085345 | Melphalan, Arsenic Trioxide, and Ascorbic Acid in Treating Patients With Relapsed or… | Phase 2 | withdrawn | Jun 11, 2004 | Oncotherapeutics | not stated | Not stated |
| NCT00112879 | Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Treating Patients With… | Phase 2 | withdrawn | Jun 3, 2005 | The Cleveland Clinic | not stated | Not stated |
| NCT00609817 | Safety and Efficacy Study of GCS-100LE in the Treatment of Multiple Myeloma | Phase 1 | terminated | Feb 7, 2008 | La Jolla Pharmaceutical Company | Lack of funding | Funding |
| NCT01617213 | Autologous Stem Cell Transplantation and Maintenance Therapy for Multiple Myeloma(AMM-2011) | Phase 2 | terminated | Jun 12, 2012 | University of Virginia | Study is no longer needed as recent data have answered the primary hypotheses for this study. | Other (stated, no rule matched) |
| NCT00968396 | Ex-Vivo Depletion of Myeloma Cells From Peripheral Blood Progenitor Cell Grafts | Phase 2 | withdrawn | Aug 31, 2009 | M.D. Anderson Cancer Center | not stated | Not stated |
| NCT01179490 | Efficacy and Safety Study of SyB L-0501 for Patients With Multiple Myeloma | Phase 2 | terminated | Aug 11, 2010 | SymBio Pharmaceuticals | not stated | Not stated |
| NCT01680796 | Dovitinib Combined With Bortezomib and Dexamethasone for Relapsed/Refractory Multiple… | Phase 1 | withdrawn | Sep 7, 2012 | University of Florida | The target drug, dovitinib, failed as a single agent in prior studies in patients with heavily… | Other (stated, no rule matched) |
| NCT01266811 | A Phase 3 Study of Siltuximab or Placebo in Combination With Velcade and Dexamethasone in… | Phase 3 | withdrawn | Dec 24, 2010 | Centocor, Inc. | Study canceled based on results of different study with similar hypothesis, investigational agent,… | Other (stated, no rule matched) |
| NCT01234974 | IGF-1 Inhibitor Pasireotide Lar in Combination With the m-TOR Inhibitor Everolimus | Phase 2 | withdrawn | Nov 4, 2010 | Milton S. Hershey Medical Center | Study never undertaken | Other (stated, no rule matched) |
| NCT01269203 | Efficacy of NF-kB Inhibition for Reducing Symptoms During Maintenance Therapy in Multiple… | Phase 2 | withdrawn | Jan 4, 2011 | M.D. Anderson Cancer Center | not stated | Not stated |
| NCT00793650 | Combination High Dose Melphalan and Autologous Peripheral Blood Stem Cell (PBSC)… | Phase 1 / Phase 2 | terminated | Nov 19, 2008 | Emory University | not stated | Not stated |
| NCT00038818 | CD8 DLI for Patients With Relapse or Residual Disease Following Allogeneic Stem Cell… | N/A | terminated | Jun 7, 2002 | M.D. Anderson Cancer Center | Low accrual. | Enrollment / accrual |
| NCT00242827 | Efficacy and Safety of Oral CEP-701 for the Treatment of Patients With Advanced Multiple… | Phase 2 | terminated | Oct 21, 2005 | Cephalon | not stated | Not stated |
| NCT00726869 | A Phase 1/2, Multi-center, Open-label, Dose-escalation Study of Elotuzumab(Humanized… | Phase 1 | terminated | Aug 1, 2008 | Abbott | Enrollment has been halted | Enrollment / accrual |
| NCT00368121 | EMMA-1 (Erbitux for Multiple Myeloma)(EMMA-1) | Phase 2 | terminated | Aug 24, 2006 | Prof. Dr. Andreas Engert | Lack of recruitable patients | Enrollment / accrual |
| NCT01492881 | Study of Vorinostat With Doxil and Bortezomib for Patients With Relapsed/Refractory… | Phase 2 | withdrawn | Dec 15, 2011 | UNC Lineberger Comprehensive Cancer Center | Doxil is currently unavailable | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Mar 4, 2015source: clinicaltrials